



BREAKTHROUGH PEPTIDE THERAPEUTICS

Market Announcements Platform  
Australian Securities Exchange

## Phylogica enters into Research and Licensing Agreement with Genentech

December 22<sup>nd</sup>, 2014

PERTH, AUSTRALIA - Phylogica Ltd (ASX: PYC), a public Australian drug discovery company, announced today that it has extended its collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), by entering into a Research and Licensing agreement to discover novel antibiotics.

Phylogica will employ its Phylomer<sup>®</sup> drug discovery platform, including its proprietary cell penetrating peptide discovery technology to identify Phylomer peptides suitable for further evaluation.

Under the terms of the agreement, Phylogica will receive an upfront payment of US\$500,000. In addition, Phylogica is eligible to receive research, development, and commercialization milestone payments totaling up to US\$142 million.

Phylogica's CEO Dr Richard Hopkins commented that: "We are delighted to continue building upon on the success of our initial collaboration with Genentech. This alliance has the potential to address an unmet need for novel antimicrobials to treat bacterial infections, including drug-resistant superbugs. "

-ends-

### For further information, please contact:

Dr Richard Hopkins  
Tel: 61 08 9489 7855  
Email: richardh@phylogica.com

Rudi Michelson  
Monsoon Communications  
Tel + 61 3 9620 3333  
Email: rudim@monsoon.com.au

### About Phylogica

*Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics from the most structurally diverse libraries available. The Company listed on the ASX in 2005 as a spin out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company's drug discovery platform is based on its proprietary Phylomer<sup>®</sup> libraries containing*



BREAKTHROUGH PEPTIDE THERAPEUTICS

*over 400 billion unique natural peptides, which have been optimised by evolutionary selection to adopt stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry, utilising its Phylomer<sup>®</sup> libraries and proprietary screening technologies in exchange for licence fees, milestones and royalties. Phylogica has entered into discovery alliances with several of the largest global Pharmaceutical companies. Partners from alliances within the last 5 years include Roche, Genentech, MedImmune, Pfizer, Janssen and Cubist Pharmaceuticals.*